Latest news with #EYLEAHD
Yahoo
29-04-2025
- Business
- Yahoo
Why Regeneron (REGN) Stock Is Falling Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell short of Wall Street's estimates. Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales, including a 29% plunge in legacy EYLEA, despite a 54% jump in EYLEA HD. Overall, this quarter could have been better. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Regeneron? Access our full analysis report here, it's free. Regeneron's shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. Regeneron is down 20.2% since the beginning of the year, and at $570.73 per share, it is trading 52.5% below its 52-week high of $1,202 from August 2024. Investors who bought $1,000 worth of Regeneron's shares 5 years ago would now be looking at an investment worth $1,106. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
Yahoo
19-04-2025
- Business
- Yahoo
Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD
On April 17, Regeneron (REGN) Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD Injection 8 mg. The sBLA seeks approval for EYLEA HD for both the treatment of macular edema following retinal vein occlusion, RVO, and for broadening the dosing schedule to include every 4-week dosing across approved indications. The FDA target action date is August 19, 2025, following the use of a Priority Review voucher. The sBLA is supported by data from across the EYLEA HD clinical program, including the Phase 3 QUASAR trial investigating EYLEA HD in RVO. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on REGN: Disclaimer & DisclosureReport an Issue Regeneron, Sanofi announce FDA approval of Dupixent for CSU Regeneron announces FDA accepted Priority Review sBLA for EYELEA HD Regeneron price target lowered to $150 from $170 at Canaccord Regeneron price target lowered to $547 from $575 at BofA Regeneron Downgraded to Sell Amid Eylea Sales Decline and Market Pressures
